ArticleClinical cancer research : an official journal of the American Association for Cancer Research2008

Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.

Rebecca B Klisovic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.